The present invention relates to a new generation of PDT agents based on porphyrin-lanthanide complexes with specific functional groups which can specifically localize on particular tumors, and their PDT processes can be monitored via NIR emission from erbium. In particular, the present invention provides a multi-modal lanthanide-porphyrin PDT agent (Er-R3) that are capable of killing the bladder tumor cells selectivity via 1O2 from porphyrin moiety and affording the fluorescence imaging simultaneously upon Er-R3 binding with the integrin αvβ3 isoform in bladder cancer cells.本發明係關於基於具有特異性官能基之卟啉-鑭系元素錯合物之新一代PDT藥劑，該等藥劑可特異性定位於特定腫瘤，且其PDT過程可經由鉺之NIR發射監測。特定言之，本發明提供多重模式鑭系元素-卟啉PDT藥劑(Er-R3)，其能夠經由來自卟啉部分之1O2選擇性殺死膀胱腫瘤細胞，且在Er-R3與膀胱癌細胞中之整合素αvβ3同功型結合時同時提供螢光成像。
